Management Team

Meet our team of leaders, researchers, and advisors.

Chief Executive Officer  

Dr. Lucas Rodriguez, MS, PhD

Dr. Rodriguez co-founded CerSci Therapeutics while completing his PhD requirements in 2015 and 2016. He received his MS and PhD degrees in Biomedical Engineering from The University of Texas at Dallas studying novel bioactive bone cement for orthopedic and craniofacial surgery and new vented dental implant abutments for the mitigation of residual excess dental luting cement in cement-retained crown prosthetics after receiving his BS in biology with a minor in chemistry from Baylor University in 2010. Dr. Rodriguez has extensive experience in the design, development, and testing, of medical devices and biomedical technologies for commercial applications. He has over 5 years of project management experience in high-tech biomedical and biotherapeutic industries. During graduate school Dr. Rodriguez pursued a concentration in Innovation and Entrepreneurship at The University of Texas at Dallas Naveen Jindal School of Management. Dr. Rodriguez has extensive experience and a background in biology, biochemistry, general & organic chemistry, and biomedical engineering (specifically in medical devices design and development). Additionally, he has developed his career in business development concentrating on strategy, business plan development, fundraising, sales, and mergers and acquisitions.

Chief Scientific Officer  

Dr. Scott Dax, MS, PhD

Dr. Scott Dax has over 25 years of experience guiding research & development at both large pharmaceutical and small biotechnology companies. His leadership roles span chemistry, drug discovery, pharmacology and technology. Prior to joining CerSci, Dr. Dax served as Chief Technology Officer at Galleon Pharmaceuticals, where he discovered and designed breathing control modulators to treat respiratory depression caused by opioid therapy without compromising analgesia. Scott’s research contributed to venture capital investments totaling greater than $60 million. Dr. Dax also served as Analgesics Research Team Leader at Johnson & Johnson. The team delivered multiple New Chemical Entities into Early Development, working in the areas of delta-selective and mixed mu / delta opioid agonists, (Transient Receptor Potential) TRPV1 and TRPM8 antagonists, mono-acylglycerol lipase inhibitors, N-type calcium channel blockers, NSAIDs (non-steroidal anti-inflammatory drugs), voltage-gated sodium channel blockers and differentiated tramadol and acetaminophen analogs. Scott also served on the Diligence team that in-licensed tapentadol later marketed as Nucynta. Prior to Johnson & Johnson, he held positions at DuPont-Merck and Hoffmann-LaRoche working in the area of infectious diseases. Dr. Dax is an inventor of over 100 issued patents worldwide and approximately 100 publications & presentations in peer-reviewed journal and professional societies. He earned his Masters and Doctorate degrees in chemistry at the University of Michigan and was an NIH post-doctoral awardee at the University of Wisconsin.

Chief Medical Officer  

Dr. Marco Pappagallo, MD

Dr. Marco Pappagallo, MD completed his medical school and a post-graduate training in neurosurgery at the University of Rome, Italy. He completed his residency training in Neurology at the State University of New York at Stony Brook. In 1990 he obtained a position as clinical and research fellow in pain medicine at Johns Hopkins University, Baltimore, MD. After his pain fellowship, he became faculty member of the Departments of Neurology, Neurosurgery and Anesthesiology and Medical Director of Chronic Pain at Hopkins. In 1999 Dr. Pappagallo moved to the Hospital of Joint Diseases – New York University, NY as Director of the Comprehensive Pain Center. In 2003 he joined the Department of Pain and Palliative Care at Beth Israel Medical Center in New York City, NY as Director of Chronic Pain. From 2006 till 2011 he worked at the Mount Sinai Medical Center, NYC, NY where he held the position of Professor and Director of Pain Research in the Department of Anesthesiology. In 2010 Dr. Pappagallo co-founded the start-up NovaPharm Therapeutics (NPT - Wayne, PA) where he operated as Chief Medical Officer. NPT001 asset was subsequently acquired by Grünenthal. Dr. Marco Pappagallo began to work with Grünenthal (GRT)-US as Medical Expert-in-Residence and Executive Director of Medical Intelligence. He collaborated with the GRT-US regulatory team in compiling the initial application concerning the Breakthrough Therapy Designation (BTD) for neridronate in CRPS, which was eventually granted by the FDA in Dec 2016. Since 2011, he has directed the New Medical Home for Chronic Pain in NYC, NY. In July 2014 Dr. Pappagallo was named Clinical Professor of Anesthesiology at the Albert Einstein College of Medicine, Bronx, NY and in January 2015 he became Co-director of the Pain Management Center at Overlook Medical Center in Summit, NJ.

Operations Manager  

Mr. Eugene Garza

Mr. Eugene Garza joined CerSci after running administrative operations for Digital Marketer in Austin, Texas. Previously he worked under renowned anthropologists Tom and Sheila Pozorski in Casma, Peru as a data analyst and field operations manager. He began his career in operations and administration in the medical sector with a focus on growth and expansion initiatives. Eugene's academic interests revolve around behavioral science in a work environment and its impact on job structure, performance, communications, motivation, and leadership. He received his B.S. in Sociology from the University of Texas Rio Grande Valley.

VP, Finance and Business Development  

Mr. Greg Dyer

Mr. Greg Dyer joined CerSci after working in management consulting with Riveron where he focused on strategic finance, M&A integration, and other value-creation projects. He has experience advising both public and private companies across a variety of industries including pharmaceuticals, technology, energy, and healthcare. Greg began his career in the energy industry managing project finances and schedules for large oil and gas capital projects internationally. Greg holds a B.S. in Finance from Texas A&M University.

Clinical and Regulatory Operations  

Ms. Teresa Byrne

Ms. Teresa Byrne is the Director of Clinical and Regulatory Operations for BioMotiv, and brings more than 17 years of pharmaceutical industry experience with her to this role. She is responsible for overseeing all Clinical and Regulatory operational functions in support of the development and progression of compounds from pre-clinical through early phase clinical research.

Teresa has broad clinical research experience, across multiple therapeutic areas including cardiovascular, pulmonary, immunology, vaccines and oncology. Prior to joining BioMotiv, Teresa was the Director of Global Clinical Operations for a small CRO, and was responsible for all clinical trial management, project management and regional monitoring activities across the global organization. For many years, Teresa held roles in clinical trial management and clinical operations at companies such as GSK, Johnson & Johnson, and Novartis Vaccines.

Teresa has a B.A. degree in biology from Rutger’s University and has done post-graduate work in clinical pharmacology at Thomas Jefferson University.